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ABSTRACT
Patients with chronic hepatitis B infection should be followed up to identify possible chang-
es in disease status, such as HBsAg seronversion. There are little data on the outcome of such 
cases, and the response rate to HBV vaccine has not been discussed extensively.
  c 2011 Kowsar M.P.Co. All rights reserved.
ARTICLE INFO
Article history:
Received: 01 Jan 2011
Revised: 04 Jan 2011









  c 2011 Kowsar M.P.Co. All rights reserved.
   * Corresponding author at: Seyed Moayed Alavian, Baqiyatallah Research Center 
for Gastroenterology and Liver Disease, Tehran, IR Iran. Tel: +98-2181262072, Fax: 
+98-2181262072.
     Email address: editor@hepatmon.com
The prevalence of occult hepatitis B (OHB) infection in HB-
sAg-seroconverted patients has not yet been reported in the 
medical literatures. Due to the unknown outcomes of these 
patients who lost HBsAg and not seroconverted to anti-HBs 
with no detectable HBV DNA, Taheri et al. (1) determined the 
efficacy of HBV vaccine in such patients during 8 years of 
follow-up.Undoubtedly, this unique study opens a new win-
dow toward HBsAg seroclearnace. Their results strengthen 
the hypothesis that chronic HBsAg-positive cases who have 
lost HBsAg and are negative for serum HBV DNA in their sera 
may still have occult HBV infection (1). Several factors influ-
ence the natural history of HBV infection, including the age 
at which the infection is acquired; viral characteristics, such 
as HBV genotype, viral mutations, and level of HBV replica-
tion, host factors, such as gender, age, and immune status; 
and exogenous factors, such as concomitant infection with 
other hepatotropic viruses or alcohol consumption. Prior 
to implementation of the national vaccination program for 
Iranian children, the main risk factor for acquiring HBV in-
fection was perinatal infection from HBsAg-positive moth-
ers to their infants during delivery (2-4). Most patients with 
chronic HBV infection are inactive carriers, and there are an 
estimated 300 million inactive carriers worldwide. The di-
agnosis of inactive HBsAg carrier is based on the absence of 
HBeAg, the presence of anti-HBe, undetectable or low levels 
of HBV DNA in PCR-based assays, repeatedly normal ALT lev-
els, minimal or no necroinflammation, slight fibrosis, and 
normal histology by biopsy (5). According to published find-
ings and due to variations in viral load, more than one HBV 
DNA test is required to make the diagnosis (6). 
One of the principal outcomes of follow up of HBV inac-
tive carriers is seronvesrsion which means becoming HBsAg 
negative and developing anti-HBs. There is a significant dif-
ference in HBsAg seroclearance rate between different stud-
ies and ethnicities. This difference could be owing to the 
difference in the occurrence time of HBV infection. In com-
munities with more adolescent infections, such as western 
countries, the incidence of delayed HBsAg clearance ranges 
from 1% to 2% per year; while a lower rates, from 0.05% to 0.8% 
per year, are reported in endemic areas, where HBV infection 
is primarily acquired perinatally or in early childhood (7). 
  Implication for health policy/practice/research/medical education: 
This editorial has been written to emphasize one of the most important articles published in 11(2) and draw reader’s attention towards it. 
Clinicians in the fields of infectious diseases and internal medicine should be aware of managing chronic carriers of HBV who experience 
negative seroconversion.  
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Although no Iranian report has been published, we estimate 
the incidence to be less than 0.5% per year (unpublished 
data). 
With regard to the meaning of seroconversion, HBsAg se-
roclearance has been defined as the loss of serum HBsAg on 
2 occasions at least 6 months apart, maintained to the study 
conclusion (8, 9). HBsAg seroclearance, which is associated 
with HBV DNA levels at baseline and follow-up, is one of the 
most important predictors of seroclearance. Higher HBV vi-
ral loads effect lower HBsAg seroclearance rates (P<0.001). A 
spontaneous decrease in follow-up HBV-DNA levels (>3 logs) 
was associated significantly with seroclearance, showed an 
adjusted odds ratio of 4.17 (95% confidence interval, 2.55–
6.82).  Among  those  who  experience  seroclearance,  95.8% 
have  undetectable  HBV  DNA  levels  before  seroclearance 
(10). Further, the clearance of HBsAg has been reported to 
be higher in women than in men and in older carriers (7).
Although the prognosis is improved by the loss of HBsAg—
because the liver disease is usually inactive and nonprogres-
sive—HBsAg clearance does not prevent the development of 
decompensation  or  Hepatocellular  carcinoma  in  patients 
who have already become cirrhotic (11). Occult hepatitis B 
(OBH) infection is an outcome of inactive carriers with HBV 
infection; thus, we should consider this issue in all cases of 
seroconversion, especially for patients in our region (12-15).
According to the previous report about the effectiveness of 
HBV vaccine in anti HBcAb positive cases, we found that 20% 
of these cases had no respond to the vaccine. Among these 
patients,  patients  with  a  positive  history  of  HBsAg  were 
more likely to be unresponsive (16). This finding supports 
the results of Taheri et al. Thanks to the main message of this 
article, however, limitations confessed by authors not to be 
ignored by readers. First, predictors, other than serum HBV-
DNA and ALT levels, were measured only at baseline because 
some of these factors can change over time. Furthermore, 
they did not measure HBV viral load. Although age, ethnic-
ity, and extreme obesity in men were significant predictors 
of HBsAg seroclearance, the comparison of serum HBV-DNA 
levels between baseline and follow-up might be the most im-
portant predictor of HBsAg seroclearance (10). Also, the au-
thors did not gather sufficient data regarding the exact time 
of HBV detection in their subjects (1). And the third limita-
tion is related to not forgetting one of the possible explana-
tions of HBsAg negativity when there is low titer of HBsAg in 
the serum.
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